Karyopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly Earnings Results


Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) posted its quarterly earnings results on Sunday. The company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.06), MarketWatch Earnings reports. Karyopharm Therapeutics had a negative return on equity of 187.66% and a negative net margin of 221.23%.

Shares of Karyopharm Therapeutics stock traded down $0.96 during trading on Tuesday, hitting $8.48. 132,535 shares of the stock traded hands, compared to its average volume of 2,426,275. The firm has a market cap of $636.52 million, a P/E ratio of -2.94 and a beta of 0.93. The company has a current ratio of 5.42, a quick ratio of 5.39 and a debt-to-equity ratio of 1.38. Karyopharm Therapeutics has a 52-week low of $8.93 and a 52-week high of $21.82. The stock’s fifty day simple moving average is $10.41 and its 200 day simple moving average is $14.01.

A number of research analysts have recently commented on the company. Zacks Investment Research downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 18th. Royal Bank of Canada decreased their price target on Karyopharm Therapeutics from $24.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday. SVB Leerink reduced their target price on Karyopharm Therapeutics from $22.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday. Barclays reduced their target price on Karyopharm Therapeutics from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, February 12th. Finally, Robert W. Baird reduced their target price on Karyopharm Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $27.00.

In related news, insider Sharon Shacham sold 9,495 shares of the firm’s stock in a transaction dated Thursday, February 18th. The stock was sold at an average price of $14.83, for a total transaction of $140,810.85. Following the sale, the insider now owns 776,452 shares of the company’s stock, valued at $11,514,783.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 14,681 shares of company stock worth $207,959. Insiders own 13.26% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1.

Recommended Story: Percentage Decliners

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.